Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial | Zendy

Inder S. Anand | Zendy; Thomas S. Rector | Zendy; Michael A. Kuskowski | Zendy; James Snider | Zendy; Jay N. Cohn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial

Author(s) -

Inder S. Anand,

Thomas S. Rector,

Michael A. Kuskowski,

James Snider,

Jay N. Cohn

Publication year - 2014

Publication title -

circulation heart failure

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 104

eISSN - 1941-3297

pISSN - 1941-3289

DOI - 10.1161/circheartfailure.113.001036

Subject(s) - valsartan , medicine , heart failure , hazard ratio , natriuretic peptide , cardiology , proportional hazards model , placebo , biomarker , clinical trial , gastroenterology , confidence interval , blood pressure , pathology , biochemistry , chemistry , alternative medicine

Soluble ST2 (sST2), a biomarker related to inflammation, is associated with outcomes of patients with heart failure. In-depth analyses of the relationship among sST2, changes in sST2, and patient outcomes are reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research